A

PTO/SB/05 (03-01)

Please type a plus sign (+) inside this box

H

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

Attorney Docket No. EPI-00311

First Inventor NYCE, Jonathan W.

Title Compositions & Formulations With An Epiandrosterone Or A Ubiquinone, & Their Use For Treatment Of Asthma Symptoms & Reducing Adenosine

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Express Mail Label No. EL 836372456 US

	ION EL EMENTO			Assi	stant Com	missio	oner for Patents
APPLICATION ELEMENTS		ADDF	RESS TO: Box	Patent Ap	plication	on	
See MPEP chapter 600 concer		ontents.			hington, l		
1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)			7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)				
Applicant claims small entity status.			8. Nucleotide and/or Amino Acid Sequence Submission				
2. See 37 CFR 1.27.		,	(if applicable, all necessary)				
3. Specification (preferred errangement se	[Total Pages	J	a. Computer Readable Form (CRF)				
- Descriptive title of	f the invention to Related Applications		b. Specification Sequence Listing on:				
- Statement Regard	ding Fed sponsored R & D		 i. CD-ROM or CD-R (2 copies); or 				
 Reference to sequ 	uence listing, a table,		i i. 🔲 paper				
or a computer pro - Background of the	ogram listing appendix		c. Statements verifying identity of above copies				
- Brief Summary of	f the Invention		ACCOMPANYING APPLICATION PARTS				N PARTS
 Brief Description Detailed Descripti 	of the Drawings (if filed)		9.14				
- Claim(s)	1011		9. Assignment Papers (cover sheet & document(s)) 37 CFR 3.73(b) Statement Power of				
- Abstract of the Di	isclosure		10. (when there is an assignee) Attorney				
△ Drawing(s) (35 U.S	S.C. 113) Total Sheets	1	11.	English Translation	Docume	nt (if a	
5. Oath or Declaration	[Total Pages	i	12.	Information Disclos Statement (IDS)/P			Copies of IDS Citations
	·) / (· ·		13. Preliminary Amendment				
a. Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) b. (for continuation/divisional with Box 18 completed)		i)) eted)	14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)				
	ON OF INVENTOR(S)	,	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)				
	ment attached deleting inventor(s) prior application, see 37 CFR		Nonpublication Peguast under 35 ILS C 122				
named in the 1.63(d)(2) an			16. (b)(2)(B)(i). Applicant must attach form PTO/SB/35				
			_	or its equivalent.			
6. Application Data Sheet. See 37 CFR 1.76			17. Other:				
18. If a CONTINUING APPLICA	ATION, check appropriate box,	and supply	the requi	site information below	and in a p	relimir	nary amendment,
or in an Application Data Shee		(CID)		prior application No.:	9 / 488	3.236	
Continuation	Divisional Continuation-in	-part (CIP)		Group Art Unit: 1614	/		
Prior application information:	NAL ARRS only: The entire discle	sure of the p	rior applic	cation, from which an oa	th or deci	aration	is supplied under
Day Shi is considered a part of t	he disclosure of the accompanyl	no continuatio	on or divis	sional application and is	: nereby in	corpor	rated by reference.
The incorporation can only be re	elled upon when a portion has be	SPONDENC			prication p	erts.	
			OL ADDI				
Customer Number or Bar Code	e Label (Insert Customer No.)26380 or Attach bar cod	de label here	θ) or	Correspon	dence ac	ddress below
Name	EpiGenesis Pharmaceut	icals, Inc.		-			
	7 Clarke Drive						
Address							
City	Cranbury	s	tate	New Jersey	Zip C	Code	08520
Country	(609) 409-3035	Teleph	hone	(609) 409-3035	Fa	ix	(413) 254-924
(Deleta 7)	Viviana Amzel, Ph.D	71	Regis	stration No. (Attorne	v/Agent)	30,9	930
Name (PrintlType)		1/-	, .cg/s	2	Date		24 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. The will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, 8ox Patent Application, Washington, DC 20231.



U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL	AMOL	TNL	OF	PAY	MENT

(\$) 845.00

spond to a collection of fillo	Illation dilless it displays a valid Chile Val				
Complete if Known					
Application Number					
Filing Date					
First Named Inventor	Jonathan W. Nyce				
Examiner Name					
Group Art Unit					
Attorney Docket No.	EPI-00311	_			

METHOD OF PAYMENT	FEE CALCULATION (continued)					
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	3. ADDITIONAL FEES Large Small					
Deposit Account 50-1728	Entity Entity					
Number	Fee Fee Fee Fee Fee Description Fee P	aid				
Account Name EpiGenesis Pharmaceuticals, Inc.	105 130 205 65 Surcharge - late filing fee or oath	\dashv				
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	127 50 227 25 Surcharge - late provisional filing fee or cover sheet	_				
Applicant claims small entity status.	139 130 139 130 Non-English specification					
See 37 CFR 1.27	147 2,520 147 2,520 For filing a request for ex parte reexamination					
2. Payment Enclosed: Check Credit card Money Other	112 920° 112 920° Requesting publication of SIR prior to Examiner action					
FEE CALCULATION	113 1,840° 113 1,840° Requesting publication of SIR after Examiner action	_				
	115 110 215 55 Extension for reply within first month	—				
1. BASIC FILING FEE	116 390 216 195 Extension for reply within second month					
Large Entity Small Entity Fee Fee Fee Fee Description	117 890 217 445 Extension for reply within third month					
Code (\$) Code (\$) Fee Paid	118 1,390 218 695 Extension for reply within fourth month					
101 710 201 355 Utility filing fee 355	128 1,890 228 945 Extension for reply within fifth month]				
	119 310 219 155 Notice of Appeal					
107 490 207 245 Plant filing fee	120 310 220 155 Filing a brief in support of an appeal					
108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing	\Box				
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding	—				
SUBTOTAL (1) (\$) 355	140 110 240 55 Petition to revive - unavoidable					
2. EXTRA CLAIM FEES	141 1,240 241 620 Petition to revive - unintentional	_				
Fee from Extra Claims <u>below</u> Fee Paid						
Total Claims 79 -20** = 50 x 9 = 450	143 440 243 220 Design issue fee					
Independent 1 - 3** = 0 x 40 = 0	144 600 244 300 Plant issue fee					
Claims Multiple Dependent =	122 130 122 130 Petitions to the Commissioner	_				
	123 50 123 50 Processing fee under 37 CFR 1.17(q)	_				
Large Entity Small Entity Fee Fee Fee Fee Fee Description	126 180 126 180 Submission of Information Disclosure Stmt					
Fee Fee Fee Fee Fee Description Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581 40 581 40 Recording each patent assignment per property (times number of properties)	40				
102 80 202 40 Independent claims in excess of 3	146 710 246 355 Filing a submission after final rejection (37 CFR § 1.129(a))					
104 270 204 135 Multiple dependent claim, if not paid	149 710 249 355 For each additional invention to be					
109 80 209 40 ** Reissue independent claims over original patent	examined (37 CFR § 1.129(b))	\dashv				
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	179 710 279 355 Request for Continued Examination (RCE) 169 900 169 900 Request for expedited examination	-				
(6) 450	Other fee (specify)					
SUBTOTAL (2) (3) 450	(0)	40				
**or number previously paid, If greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$)					

SUBMITTED BY

Name (PrintlType)

Vivjana Amzel, Ph.D.

Registration No. (Attorney/Agent)

30,930

Telephone (609) 409-3034

Signature

Date April 2 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re CIP Application of:

Applicant:

Nyce, J. W.

: Group Art Unit:

Serial No:

: Appl. Ref. No:

EPI-00311

Filed:

herewith

: Examiner:

Title:

COMPOSITIONS & FORMULATIONS WITH AN EPIANDROSTERONE OR A UBIQUINONE & KITS & THEIR USE FOR TREATMENT OF ASTHMA SYMPTOMS & FOR REDUCING ADENOSINE/ADENOSINE RECEPTOR

LEVELS

COVER SHEET

Assistant Commissioner for Patents Washington DC 20203

Sir/Madam:

The following documents are enclosed:

- 1. Utility Patent Application Transmittal Form (1 pg)
- 2. Application Cover Sheet, Specification, Claims & Abstract (31 pgs)
- 3. Declaration/Power of Attorney (3 pgs)
- 4. Assignment of Application (2 pgs)
- 5. Assignment Recordation Form Cover Sheet (2 pgs)
- 6. Fee Transmittal Form (1 pg)
- 7. Return Post Card
- 8. Express Mail Label EL836372456 US

Respectfully submitted.

EPIGENESIS PHARMACEUTICALS, INC.

Date: April 24, 2001

Viviana Amzel, Ph.D. Registration No. 30,930

Attorney for the Applicant

7 Clarke Drive Cranbury, NJ 08512 609-409-3035 Ph. Direct 413-254-9245 Fax Legal Dpt. Vamzel@epigene.com

S:\LegaN0031 DHEA ASTHMA\00311\Cover sheet 01-4-23.doc